SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 6,872 shares, an increase of 117.6% from the May 31st total of 3,158 shares. Based on an average daily trading volume, of 38,353 shares, the days-to-cover ratio is currently 0.2 days.
SAB Biotherapeutics Price Performance
Shares of SABSW stock opened at $0.01 on Thursday. The stock has a 50 day moving average price of $0.02 and a 200 day moving average price of $0.03. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.18.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Recommended Stories
- Five stocks we like better than SAB Biotherapeutics
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
